The cleanest diagnosis of Walgreens is not bad strategy. It is governance misalignment. The company made a major pivot into healthcare delivery, but the people, reporting structure, and board capability needed to govern that pivot were never truly aligned. The result was an organisation trying to execute a healthcare model without the leadership architecture required to know whether it was working.
What Actually Happened
Walgreens Boots Alliance emerged from the 2014 Walgreens–Alliance Boots combination as a global pharmacy giant with scale, brand equity, and a market value near $100 billion. Stefano Pessina, who had built Alliance Boots and retained a major ownership stake, became central to the combined company's direction. His strategic instinct was that retail pharmacy alone was no longer enough. The company needed to move closer to care delivery.
That strategic instinct was not irrational. Margin pressure in pharmacy, Amazon's encroachment, and the need for differentiated healthcare positioning were real. CVS had already demonstrated that healthcare adjacency could matter. But Walgreens did not build the same structural underpinnings. Instead, it pursued VillageMD and related healthcare assets without controlling the insurer relationship that made the economics of value-based care more viable elsewhere.
2015: Walgreens Boots Alliance sits near a $100 billion valuation, with Stefano Pessina as CEO and the architect of the combined company's strategic direction.
2020: Walgreens commits initial capital to VillageMD, beginning a healthcare delivery pivot built around primary care clinics attached to pharmacy locations.
2021: Pessina moves from CEO to executive chairman, retaining substantial influence. The board appoints Rosalind Brewer as CEO despite her lack of healthcare operating experience. Walgreens deepens its VillageMD commitment and expands related healthcare bets.
2021–2023: VillageMD expands and Walgreens increases exposure, but profitability does not materialise on the timeline implied by the strategy.
2023: Brewer exits. The company publicly signals the need for leadership with deeper healthcare experience, implicitly acknowledging the earlier CEO-strategy mismatch.
2024: Walgreens is removed from the Dow. The company takes a massive impairment charge tied to VillageMD and acknowledges the business model is "non-sustainable" in its current form.
2025: Walgreens is taken private in a transaction that values the equity at a fraction of its historic peak.
The key issue is not that Brewer was an ineffective executive. It is that the board asked a retail and consumer operator to execute a complex healthcare services transformation while the designer of that strategy remained structurally powerful above her. That is not an execution problem first. It is a governance design problem first.
"The Walgreens failure was not just that the strategy underperformed. It was that the person charged with executing it was never positioned to independently evaluate, challenge, or reframe it."
The Five NAVETRA™ Domains That Were Failing
Walgreens maps clearly onto five NAVETRA™ domains because the failure was not contained to one decision. Strategy, board capability, leadership appointment, and execution structure were all misaligned at once.
Was the board, executive chairman, and CEO aligned around one independently testable view of whether the healthcare strategy could work?
At Walgreens: no. Pessina designed the healthcare direction and retained strong influence as executive chairman. Brewer was tasked with execution but did not bring deep healthcare expertise or structural independence from the strategy's architect. The board therefore lacked a clean internal mechanism for separating strategic advocacy from strategic evaluation.
Was Walgreens structurally organised to behave like a healthcare delivery company, or was it still fundamentally a retail pharmacy company buying healthcare assets?
At Walgreens: the company never fully solved that integration problem. Clinics inside stores do not automatically create a healthcare platform. Without the surrounding payer, reimbursement, and care-model infrastructure, the organisation remained a retail company trying to behave like an integrated care company. That is an organisational alignment failure, not just an M&A failure.
Did the board appoint a CEO whose capabilities matched the transformation underway?
At Walgreens: the board appointed an accomplished operator with strong consumer and retail credentials, but not the domain background the company itself later admitted it needed. That is the core hiring friction signal in this case. The mismatch was visible from the outset. The company was moving deeper into healthcare while choosing leadership optimized for a different domain.
Did the board independently stress-test the strategy against external realities such as CVS's structural advantage, payer economics, pharmacy margin compression, and Amazon's pressure?
At Walgreens: the signals were available. CVS had already shown the value of tighter vertical integration through Aetna. Retail pharmacy economics were worsening. Competing healthcare pivots elsewhere were mixed or failing. Yet Walgreens continued committing capital without clear evidence that its version of the model had a structurally advantaged path to profitability.
Were the retail, finance, healthcare, and governance functions working from one integrated profitability picture?
At Walgreens: the evidence suggests they were not. The healthcare assets and the legacy retail pharmacy footprint were presented as part of one transformation story, but the financial and operating logic connecting them remained weak. Cross-functional alignment failed because the organisation could describe the strategy, but it could not demonstrate a unified model that made the components economically coherent together.
The CVS Comparison — Same Threat, Different Governance
The most useful comparison is CVS. Both companies faced retail pharmacy pressure. Both saw the need to move closer to care delivery. CVS acquired Aetna and built around payer control. Walgreens pursued a more fragmented partner-based path. That difference is not merely strategic. It is governance-relevant. One board approved a transformation with an economic anchor. The other approved one without the same structural core.
This is the heart of the case. Walgreens did not merely choose a hard strategy. It chose a hard strategy without ensuring the board and executive structure had the expertise and independence to determine whether the missing structural pieces made the strategy non-viable from the beginning.
$100 billion to roughly $10 billion in equity value. Billions committed to VillageMD. Billions written off. A healthcare transformation designed by an executive chairman and executed by a CEO without healthcare operating depth. Walgreens is a case study in board-level strategy–leadership mismatch: the board approved a pivot whose success depended on domain-specific execution, then installed leadership that was not structurally equipped to independently evaluate or reshape that pivot.
The market pressure was real. The destruction of value was governance-shaped.
The Question for Every Board Governing a Strategic Pivot
Every board overseeing a major pivot into an adjacent sector should ask one hard question: do we actually possess the domain expertise and executive architecture to know whether this strategy is viable before the impairment tells us? That is the Walgreens question.
NAVETRA™ does not ask whether the strategy sounded compelling. It asks whether the leadership, board capability, and organisational structure were aligned to test it honestly. At Walgreens, they were not. That is why the transformation consumed capital long after the governance architecture should have forced a harder answer.
The costliest strategic pivot is the one governed by people who cannot independently determine whether its missing structural component makes success impossible.